NCT05496439

Brief Summary

Study of the prognosis of patients with heart failure with preserved ejection fraction

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
172

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2020

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 22, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 6, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 5, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 11, 2022

Completed
Last Updated

August 11, 2022

Status Verified

August 1, 2022

Enrollment Period

2.2 years

First QC Date

August 5, 2022

Last Update Submit

August 10, 2022

Conditions

Heart Failure With Preserved Ejection Fraction

Keywords

visceral fat area

Outcome Measures

Primary Outcomes (1)

  • death

    all-cause death

    The median follow-up time of 395.5 days(interquartile range: 207.5 to 535.5 days)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with heart failure with preserved ejection fraction

You may qualify if:

  • Adult aged \>=18years old;
  • Diagnosed with HFpEF.Diagnostic criteria including:
  • ）left ventricular ejection fraction ≥50%； 2）with the symptoms and/or signs of heart failure； 3）BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL； 4）at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction

You may not qualify if:

  • Age \<18 years old；
  • LVEF less than 45% at any time;
  • cancer diagnosis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, China

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
clinical professor

Study Record Dates

First Submitted

August 5, 2022

First Posted

August 11, 2022

Study Start

March 1, 2020

Primary Completion

May 22, 2022

Study Completion

July 6, 2022

Last Updated

August 11, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)